Seaport Therapeutics Inc（SPTX）股票分析SPTXSeaport Therapeutics Inc

Seaport Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Its product candidate, GlyphAllo (SPT-300 or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in third-party trials for the treatment of postpartum depression. GlyphAgo (SPT-320 or Glyph Agomelatine), is a novel, Glyphed oral prodrug of agomelatine, a clinically validated anxiolytic and antidepressant that is approved for the treatment of generalized anxiety disorder. It is also advancing Glyph2BLS (SPT-348 or Glyph 2-bromo-LSD), a novel, Glyphed oral prodrug of the non-hallucinogenic LSD analog 2-bromo-LSD, in preclinical studies for depressive disorders. GlyphAllo is designed to overcome the bioavailability limitations of allopregnanolone and be durable in MDD. It operates in the Healthcare sector.

Seaport Therapeutics (SPTX) is a good buy right now due to its current price of $20.61, which is significantly lower than the average analyst price target of $37.13, indicating a potential upside of 72.61%. Additionally, the stock has shown a strong 5-day change of +15.59%, reflecting positive momentum. However, the main risk is the negative earnings trend, with a projected EPS of -0.58 for the next earnings report, which could impact investor sentiment.